EORTC 2238 "De-Escalate" : a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors
Grisay, Guillaume (Centres Hospitaliers Universitaires HELORA)
Turco, Fabio (Oncology Institute of Southern Switzerland)
Litiere, Saskia (European Organization for Research and Treatment of Cancer (EORTC))
Fournier, Béatrice (European Organization for Research and Treatment of Cancer (EORTC))
Patrikidou, Anna (Genito-Urinary Oncology Group and Early Drug Development (DITEP))
Gallardo, Enrique (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
McDermott, Ray (St Vincents University Hospital and Cancer Trials)
Alanya, Ahu (European Organization for Research and Treatment of Cancer (EORTC))
Gillessen, Silke (Università della Svizzera Italiana)
Tombal, Bertrand (Cliniques Universitaires Saint Luc)

Date:	2024
Abstract:	The landscape of treating metastatic prostate cancer has evolved with the addition of Androgen Receptor pathway inhibitor (ARPI) to Androgen Deprivation Therapy (ADT), significantly improving survival rates. However, prolonged use of these therapies introduces notable side effects, prompting a need to revisit intermittent treatment duration. The EORTC 2238 De-Escalate trial is a pragmatic trial seeking to reassess the role of intermittent therapy in patients undergoing maximal androgen blockade (MAB) for metastatic hormone naïve prostate cancer (mHNPC), i. e. , the combination of ADT with an ARPI, with the aims of reducing side effects, enhancing Quality of Life (QoL) and optimizing resource usage, while maintaining oncological benefits.
Grants:	European Commission 101104574
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	mHNPC ; De-escalation ; Maximal androgen blockade ; AR pathway inhibitor ; Quality of life
Published in:	Frontiers in Oncology, Vol. 14 (May 2024) , art. 1391825, ISSN 2234-943X

DOI: 10.3389/fonc.2024.1391825
PMID: 38779087

6 p, 585.8 KB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles